Floatz logo

ERGOCALCIFEROLUM

Cholestatic Liver Disease

Chulalongkorn UniversitySmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cholestatic Liver Disease cohort.

Asset / SponsorPhaseRating
Linerixibat
GlaxoSmithKline
Phase 3BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
lum001
Mirum Pharmaceuticals, Inc.
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Tauroursodeoxycholic
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3B

View all 24 →

Same molecule, other indications

ERGOCALCIFEROLUM is also rated in:

vitamin D deficiencyDormant
BB
Indicative ·
64 / 100
View asset →
secondary hyperparathyroidismDormant
BB
Indicative ·
64 / 100
View asset →
liver disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →